An unbiased approach to defining bona fide tumor neoepitopes that mediate cancer immunity
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA681865 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Identification of neoepitopes that are effective in cancer therapy is a major challenge in creating cancer vaccines. Here, using an entirely unbiased approach, we have queried all possible neoepitopes in a mouse cancer model and asked which of those are effective in mediating tumor rejection, and independently, in eliciting a measurable CD8 response. This analysis uncovers a new universe of effective anticancer neoepitopes which have strikingly different properties from conventional epitopes and suggests a novel algorithm to predict them. It also reveals that our current methods of prediction discard the majority of true anticancer neoepitopes. These results from a single mouse model have been validated in another, independent mouse cancer model, and are consistent with data with human studies. T cells elicited by the active neoepitopes identified here demonstrate a stem-like early dysfunctional phenotype associated with effective responses against viruses and tumors of transgenic mice. These abundant and novel anticancer neoepitopes can be exploited for generation of personalized human cancer vaccines.
2020-12-15 | GSE162432 | GEO
Project description:CD74-NRG1 fusion as an bona fide oncogene
| PRJNA762691 | ENA
Project description: Not available
| S-EPMC7843235 | biostudies-literature
Project description:Staphylococcus aureus bona fide sRNAs in the model strain HG003
| PRJNA414251 | ENA
Project description:Accurate annotation of regulatory RNAs is a complex task but nevertheless essential as sRNA molecular and functional studies ensue from it. Several formerly considered small RNAs (sRNA) are now known to be parts of UTR transcripts. In light of experimental data, we review hundreds of Staphylococcus aureus putative regulatory RNAs. We pinpoint those that are likely acting in trans and are not expressed from the opposite strand of a coding gene. We conclude that HG003, a NCTC8325 derivative strain, has about 50 bona fide sRNAs, indicating that these RNAs are less numerous than commonly stated.
2018-03-07 | GSE104971 | GEO
Project description:The post-translational modification of proteins by ubiquitination is a highly regulated process that involves a dynamic, three-step enzymatic cascade, where more than 600 E3 ligases play a critical role in recognizing specific substrates for modification. Separating bona fide targets of E3s from E3-interacting proteins remains a major challenge in the field. In this study, we present BioE3, a novel approach for identifying substrates of ubiquitin-like (UbL) E3 ligases of interest. Using BirA-E3 ligase fusion proteins and bioUbLs, the method facilitates site-specific biotinylation of UbL-modified substrates for proteomic identification. We demonstrate that the BioE3 system can identify both known and novel targets of two RING-type ubiquitin E3 ligases: RNF4, known to be involved in DNA damage response and the regulation of PML nuclear bodies, and MIB1, implicated in endocytosis, autophagy, and centrosomal protein homeostasis. We further show the versatility of BioE3 by identifying targets of an organelle-specific E3 (MARCH5) and a relatively uncharacterized E3 (RNF214). Furthermore, we show that BioE3 works with HECT-type E3 ligases and identify novel targets of NEDD4 involved in vesicular trafficking. BioE3 is a powerful tool that enables identification of bona fide substrates of UbL E3 ligases and how they change with chemical perturbations, which may be useful for the emerging applications in targeted protein degradation (TPD). BioE3 may also be applicable for UbLs beyond Ub and SUMO, as well as other E3 ligase classes. The resulting knowledge can shed light on the regulation of cellular processes by the complex UbL network, advancing our understanding of fundamental biological mechanisms.
2024-01-26 | PXD041685 | Pride
Project description:Dynamic interactions between RNA and RNA-binding proteins (RBPs) regulate a broad spectrum of bacterial functions. Here, we have characterised how the RBPome is dynamically rewired during the E. coli life cycle. We applied Orthogonal Organic Phase Separation (OOPS) coupled with an RNase digestion step to shortlist bona fide bacterial RBPs and assessed whether proteins bound RNA differentially express at different cell proliferation stages.
2024-03-20 | PXD043373 | Pride
Project description:Bona fide and bystander memory B cell subsets colonize the lung peribronchial niche upon viral infection
| PRJNA731109 | ENA
Project description:Memory B cells (MBCs) are key cellular components of long-term humoral immunity that dominate recall responses by rapidly differentiating into effector cells. As the biology of MBCs has been mainly studied in the context of model antigen immunizations, the dynamics of these cells during infection remains largely unexplored. Here, we combined influenza and SARS-CoV-2 infection models with fluorescent-reporter mice to identify MBCs regardless of antigen-specificity. scRNA-seq analysis and confocal imaging revealed that two main transcriptionally distinct subsets of MBCs colonize the lung airways after infection. These subsets were class-switched, somatically mutated and preferentially differentiated into plasma rather than germinal center cells upon activation. Combined analysis of antigen-specificity and B cell receptor repertoire unveiled a highly permissive selection process that segregated these subsets into “bona fide” virus-specific MBCs and “bystander” MBCs with no apparent specificity for eliciting viruses. Thus, diverse transcriptional programs in MBCs are not linked to specific effector fates but rather to divergent strategies of the immune system to simultaneously provide rapid protection from re-infection while diversifying the initial B cell repertoire.
2022-06-02 | GSE174682 | GEO
Project description:Cross-presentation by type 1 DCs (cDC1) is critical to induce and sustain antitumoral CD8 T cell responses to model antigens, in various tumor settings. However, the impact of cross-presenting cDC1 and the potential of DC-based therapies in tumors carrying varied levels of bona-fide neoantigens (neoAgs) remains unclear. We develop a hypermutated model of non-small cell lung cancer, encoding genuine MHC-I neoepitopes to study neoAgs-specific CD8 T cell responses in spontaneous settings and upon Flt3L+CD40 (DC-therapy). We find that cDC1 are required to generate broad CD8 responses against a range of diverse neoAgs. DC-therapy promotes immunogenicity of weaker neoAgs and strongly inhibits the growth of high tumor-mutational burden (TMB) tumors. In contrast, low TMB tumors respond poorly to DC-therapy, generating mild CD8 T cell responses that are not sufficient to block progression. scRNA transcriptional analysis, immune profiling and functional assays unveil the changes induced by DC-therapy in lung tissues, which comprise accumulation of cDC1 with increased immunostimulatory properties and decreased exhaustion in effector CD8 T cells. We conclude that boosting cDC1 activity is critical to broaden the diversity of anti-tumoral CD8 T cell responses and to leverage neoAgs content for therapeutic advantage.
2024-03-04 | GSE260743 | GEO